Janux Therapeutics Inc. (JANX)
JANX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1817713/000119312526076918/0001193125-26-076918-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | JANX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001817713 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $10.0M |
| Net income | -$113.6M |
| Operating income | -$157.7M |
| Net margin | -1136.3% |
| Operating margin | -1576.7% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $52.3M |
| Total assets | $1.0B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 105.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-12-05 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-06 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 440 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.4% |
| 1 month | +4.2% |
| 3 months | +8.1% |
| Year to date | +24.1% |
| 1 year | -34.9% |
| From 52-week high | -50.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AVLN | Avalyn Pharma Inc. | $23.74 | -4.27% | $1.1B |
| HROW | Harrow Inc. | $28.24 | -2.99% | $1.1B |
| LTGO | Latigo Biotherapeutics Inc. | $15.71 | -1.94% | $1.0B |
| NBTX | Nanobiotix S.A. | $21.49 | -8.16% | $1.1B |
| AMPH | Amphastar Pharmaceuticals Inc. | $26.05 | -2.65% | $1.1B |
| OPK | OPKO Health Inc. | $1.32 | -4.35% | $985.2M |
| LBRX | LB Pharmaceuticals Inc | $34.79 | -3.17% | $1.1B |
| SVRA | Savara Inc. | $4.78 | -1.24% | $982.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier